BPC-157
Also known as: Body Protection Compound-157 · Bepecin
Contents
MW
1419.53 Da
Amino Acids
15 AA
Half-Life
4 hours
Route
SubQ, IM, Oral
CAS
137525-51-0
Formula
C62H98N16O22
Amino Acid Sequence
GEPPPGKPADDAGLV
Mechanism of Action
BPC-157 is a 15-amino acid pentadecapeptide derived from a cytoprotective protein in human gastric juice. It exerts pleiotropic healing effects through at least six distinct molecular pathways operating simultaneously.
PATHWAY 1 — ANGIOGENESIS (Primary): Upregulates VEGF (vascular endothelial growth factor) and its receptor VEGFR2, driving new capillary formation essential for nutrient delivery to damaged tissue. Also upregulates eNOS (endothelial nitric oxide synthase), producing NO for vasodilation and blood flow. This is the dominant mechanism explaining accelerated tendon, muscle, and bone healing in >100 animal studies.
PATHWAY 2 — GH RECEPTOR SENSITIZATION: Enhances GH receptor expression on tendon fibroblasts (confirmed in vitro, Sikiric et al.), potentiating downstream IGF-1 and collagen synthesis signaling even without exogenous GH. This partially explains why BPC-157 stacks synergistically with CJC-1295/Ipamorelin.
PATHWAY 3 — FAK-PAXILLIN SIGNALING: Activates focal adhesion kinase (FAK) and paxillin, the machinery that drives cell migration and ECM remodeling during tissue repair. This pathway explains accelerated wound closure and the ability to heal previously non-healing injuries in animal models.
PATHWAY 4 — NF-κB INHIBITION (Anti-inflammatory): Downregulates NF-κB transcription factor, reducing TNF-α, IL-1β, and IL-6 production. This creates the anti-inflammatory environment required for proper healing without suppressing the immune response entirely.
PATHWAY 5 — NITRIC OXIDE SYSTEM: Modulates both iNOS and eNOS, regulating tissue protection, neurotransmitter signaling, and gut mucosal protection. Unique among peptides in having direct NO system interaction explaining its neuroprotective and GI effects.
PATHWAY 6 — GI MUCOSAL PROTECTION: Upregulates prostaglandins, EGF (epidermal growth factor), and promotes tight junction protein expression. Counteracts NSAID-induced ulceration, restores gut barrier integrity (leaky gut), and accelerates healing of IBD-related mucosal damage. Notably, BPC-157 retains partial stability in gastric acid — allowing oral administration for GI-specific effects, unique among research peptides.
2025 SYSTEMATIC REVIEW (Vasireddi et al., 544 articles screened, 36 included): Confirmed GH receptor upregulation and multiple angiogenesis/cell-growth pathway activation while reducing inflammatory cytokines across 35 preclinical studies. One human retrospective: 7/12 intra-articular injection patients reported >6 months knee pain relief.
Dosing Protocol
Low Dose
███ – ███ mcg/day
Standard Dose
███ mcg/day
High Dose
███ – ███ mcg/day
Dosing protocols are for paid members
Get exact dosing ranges, injection frequency, timing rationale, and reconstitution math.
Get Clinical Access — $79/moFrequency
Once or twice daily.
Half-Life
4 hours
Reconstitution Guide
Full reconstitution protocol with BAC water volumes, concentration math, and units-to-draw per dose is available on the Clinical plan.
Unlock reconstitution guide →Clinical Warnings
FDA CATEGORY 2 BULK DRUG SUBSTANCE (2023): BPC-157 cannot be legally compounded by 503A or 503B pharmacies for human use in the USA. Any US source is operating outside FDA oversight.
WADA PROHIBITED: Listed under S0 Non-Approved Substances. Ineligible for all competitive athletes.
PRODUCT QUALITY UNVERIFIED: No FDA-approved manufacturing standard exists. Purity, sterility, and dosing accuracy cannot be guaranteed from gray-market suppliers. Demand third-party COA.
CANCER CAUTION: BPC-157 promotes angiogenesis via VEGF upregulation — the same mechanism that can support tumor vascularization. No confirmed human cancer cases but theoretical risk warrants absolute contraindication with active malignancy.
IMMUNOGENICITY: FDA flagged potential immunogenicity concerns during Category 2 review.
NO PHASE 3 HUMAN DATA: All therapeutic claims are extrapolated from animal models.
Contraindications
Absolute
Active cancer
Pregnancy
Relative Cautions
Autoimmune disease
Current anticoagulant therapy
Side Effect Profile
Mild
- ●Mild nausea
- ●Injection site redness
- ●Dizziness
Moderate
- ●Headache
- ●Fatigue
Synergistic Peptides
Common Stacks
TB-500
GHK-Cu
Research Status
LIMITED HUMAN DATA — STRONG PRECLINICAL BASE. Animal studies: 35 included in 2025 systematic review (Vasireddi et al., HSS Journal). 544 total articles screened 1993–2024. Consistent results across muscle, tendon, ligament, bone, and gut healing models. Human studies published: (1) Interstitial cystitis pilot (Lee et al., Altern Ther Health Med, 2024, PMID 38019193): 12 patients, intravesical injection, 80–100% symptom resolution — first published human intravesical BPC-157 study. (2) Chronic knee pain case series (2021): 16 patients, intra-articular injection, 87.5% reported significant relief at 6–12 months. (3) IV safety pilot (Lee & Burgess, Altern Ther Health Med, 2025, PMID 40131143): 2 healthy adults, 10 mg then 20 mg IV over 1 hour, no adverse events, no changes in cardiac/hepatic/renal/thyroid/glucose biomarkers, plasma BPC-157 returned to baseline within 24 hours. No Phase 1/2/3 RCTs completed. Evidence level: compelling animal, very limited human. FDA Category 2 bulk substance (2023).
Frequently Asked Questions
How does BPC-157 work?
BPC-157 is a 15-amino acid pentadecapeptide derived from a cytoprotective protein in human gastric juice. It exerts pleiotropic healing effects through at least six distinct molecular pathways operating simultaneously. PATHWAY 1 — ANGIOGENESIS (Primary): Upregulates VEGF (vascular endothelial growth factor) and its receptor VEGFR2, driving new capillary formation essential for nutrient delivery to damaged tissue. Also upregulates eNOS (endothelial nitric oxide synthase), producing NO for vasodi
What is the standard dose of BPC-157?
BPC-157 dosing protocols are available with a ClinPep Clinical subscription. Dosing varies by indication and patient factors — consult a licensed healthcare provider. General frequency: Once or twice daily.
What is the half-life of BPC-157?
The half-life of BPC-157 is 4 hours. This determines optimal dosing frequency and timing.
Who should not use BPC-157?
BPC-157 is absolutely contraindicated in: Active cancer; Pregnancy. Use with caution in: Autoimmune disease; Current anticoagulant therapy.
What are the side effects of BPC-157?
Common mild side effects include: Mild nausea, Injection site redness, Dizziness. Moderate effects: Headache, Fatigue.
What peptides stack well with BPC-157?
BPC-157 is commonly stacked with: TB-500, GHK-Cu, CJC-1295, Ipamorelin.
How do you reconstitute BPC-157?
BPC-157 is reconstituted with bacteriostatic water. Exact volumes, concentrations, and units-to-draw calculations are available in the ClinPep Clinical plan. Always follow your compounding pharmacy's instructions.
How long should you cycle BPC-157?
BPC-157 cycle protocols vary by indication. Detailed cycle length, on/off schedules, and monitoring guidelines are available with ClinPep Clinical access. Consult your healthcare provider for personalized cycling guidance.
References & Citations
10 PubMed studies · 2 clinical trials
Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.
Masnec Sanja, Kokot Antonio, Kralj Tamara, Zlatar Mirna et al.. Pharmaceuticals (Basel, Switzerland). 2025
To better address the challenge of corneal ulcer healing, with already available standard agents, and those recently introduced, such as stable gastric pentadecapeptide BPC 157, we introduced a novel
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.
Sikiric Predrag, Seiwerth Sven, Skrtic Anita, Staresinic Mario et al.. Pharmaceuticals (Basel, Switzerland). 2025
The healing issue is a central, not completely understood, problem in pharmacology, approached by many concepts. One of the most well-known is Robert's and Szabo's concept of cytoprotection, which hol
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
McGuire Flynn P, Martinez Riley, Lenz Annika, Skinner Lee et al.. Current reviews in musculoskeletal medicine. 2025
This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the
Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).
Whitehouse Michael. Inflammopharmacology. 2025
This article discusses the lengthy review by Pedrag Sikiric and twenty one (21) co-authors in Inflammopharmacology (2024) 32:3119-3161.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi Nikhil, Hahamyan Henrik, Salata Michael J, Karns Michael et al.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2025
Background: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. Preclinical studies show its potential for promoting healin
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.
Sikiric Predrag, Seiwerth Sven, Skrtic Anita, Staresinic Mario et al.. Pharmaceuticals (Basel, Switzerland). 2025
Although approached through many concepts, the pleiotropic healing issue, specifically, maintaining/reestablishing tissue integrity, remains a central challenge in pharmacology, particularly when the
Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.
Sikiric Predrag, Seiwerth Sven, Skrtic Anita, Staresinic Mario et al.. Pharmaceuticals (Basel, Switzerland). 2025
In this study, pharmacotherapies of abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) in animal studies were reviewed from the perspective of ACS/IAH as failed cytoprotection
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
Józwiak Michalina, Bauer Marta, Kamysz Wojciech, Kleczkowska Patrycja. Pharmaceuticals (Basel, Switzerland). 2025
BPC 157, known as the "Body Protection Compound", is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking m
Registered Clinical Trials
PCO-02 - Safety and Pharmacokinetics Trial
BPC 157 for Acute Hamstring Muscle Strain Repair
Symptom Indications
Full Clinical Access
Complete BPC-157 Protocol
Access reconstitution math, cycle guides, drug interaction checker, stack builder with contraindication analysis, symptom checker, and downloadable PDF handouts.
Secure payment powered by Stripe.
This information is for educational and research reference purposes only. ClinPep does not provide medical advice, diagnosis, or treatment recommendations. All protocols should be reviewed by a licensed healthcare provider.